Using serum glycomics to predict liver cancer recurrence after transplantation
Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular Carcinoma
This study is testing whether changes in certain sugars in the blood can help predict if liver cancer will come back in patients who have had a liver transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Ghent Academic / other |
| Locations | 1 site (Ghent) |
| Trial ID | NCT05866783 on ClinicalTrials.gov |
What this trial studies
This study aims to validate the prognostic value of serum glycomics as biomarkers for disease recurrence in liver transplant recipients diagnosed with hepatocellular carcinoma (HCC). By analyzing specific changes in N-glycan profiles before liver transplantation, the researchers hope to identify patients at higher risk for tumor recurrence and overall mortality. The study will be conducted across multiple centers, enhancing the reliability of the findings. It builds on previous pilot studies that indicated a strong association between glycan changes and HCC outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with hepatocellular carcinoma who are eligible for or on the waiting list for liver transplantation.
Not a fit: Patients with other liver tumors, such as liver metastasis or cholangiocarcinoma, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable method for predicting liver cancer recurrence, allowing for better patient management and treatment planning.
How similar studies have performed: Previous studies have shown promising results in using glycomic profiles as prognostic indicators in liver cancer, suggesting that this approach may be viable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed and dated patient informed consent document * Diagnosis of hepatocellular carcinoma * Age ≥ 18 years * Ability to comply with protocol-specified evaluations and scheduled visits * Eligible for liver transplantation and/or active on the waiting list for liver transplantation * Consulted the department of Gastroenterology and Hepatology Exclusion Criteria: * Diagnosis of other liver tumors (eg. liver metastasis, cholangiocarcinoma)
Where this trial is running
Ghent
- Ghent University Hospital — Ghent, Belgium (Recruiting)
Study contacts
- Study coordinator: Xavier Verhelst, MD, PhD
- Email: xavier.verhelst@uzgent.be
- Phone: +32 9 332 23 71
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.